Volume 7 Issue 4
Jul.  2016
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2016  >  7(4): 243-254

doi: 10.3969/j.issn.1674-7445.2016.04.001
  • Received Date: 2016-05-19
    Available Online: 2021-01-19
  • Publish Date: 2016-07-15
    Abstract
    • FullText(HTML)
  • loading
    • References(57)
  • [1]
    中国成人血脂异常防治指南制订联合委员会. 中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419.

    Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults[J]. Chin J Cardiol,2007,35(5):390-419.
    [2]
    中华人民共和国卫生和计划生育委员会. 2014中国卫生和计划生育统计年鉴[M]. 北京:中国协和医科大学出版社, 2014.

    National Health and Family Planning Commission of the People's Republic of China. Stistical yearbook of health and family planning of 2014 in China[M]. Beijing: China Union Medical University Press, 2014.
    [3]
    李莹,陈志红,周北凡,等. 血脂和脂蛋白水平对我国中年人群缺血性心血管病事件的预测作用[J].中华心血管病杂志,2004,32(7):643-647. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHXX200407022.htm

    Li Y, Chen ZH, Zhou BF, et al. The predictive effects of lipids and lipoproteins on the incidence of ischemic cardiovascular disease in middle aged Chinese population[J]. Chin J Cardiol,2004,32(7):643-647. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHXX200407022.htm
    [4]
    刘静,赵冬,秦兰萍,等. 低密度脂蛋白胆固醇与心血管病发病关系的前瞻性研究[J].中华心血管病杂志,2001,29(9):561-565. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHXX200109019.htm

    Liu J, Zhao D, Qin LP, et al. Association of low density lipoprotein cholesterol with cardiovascular disease in a prospective study[J]. Chin J Cardiol, 2001,29(9):561-565. http://www.cnki.com.cn/Article/CJFDTOTAL-ZHXX200109019.htm
    [5]
    Lentine KL, Costa SP, Weir MR, et al. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation[J]. Circulation,2012,126(5):617-663. doi: 10.1161/CIR.0b013e31823eb07a
    [6]
    Gonyea JE, Anderson CF. Weight change and serum lipoproteins in recipients of renal allografts[J]. Mayo Clin Proc,1992,67(7):653-657. doi: 10.1016/S0025-6196(12)60720-4
    [7]
    Ojo AO. Cardiovascular complications after renal transplantation and their prevention[J]. Transplantation,2006,82(5):603-611. doi: 10.1097/01.tp.0000235527.81917.fe
    [8]
    Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation[J]. Transplantation,2001,72(6 Suppl):S5-S8. http://cn.bing.com/academic/profile?id=2332741537&encoded=0&v=paper_preview&mkt=zh-cn
    [9]
    Dopazo C, Bilbao I, Castells LL, et al. Analysis of adult 20-year survivors after liver transplantation[J]. Hepatol Int,2015,9(3):461-470. doi: 10.1007/s12072-014-9577-x
    [10]
    Laryea M, Watt KD, Molinari M, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events[J]. Liver Transpl,2007,13(8):1109-1114. doi: 10.1002/(ISSN)1527-6473
    [11]
    Issa DH, Alkhouri N. Long-term management of liver transplant recipients: a review for the internist[J]. Cleve Clin J Med,2015,82(6):361-372. http://cn.bing.com/academic/profile?id=2396193086&encoded=0&v=paper_preview&mkt=zh-cn
    [12]
    Laish I, Braun M, Mor E, et al. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events[J]. Liver Transpl,2011,17(1):15-22. doi: 10.1002/lt.v17.1
    [13]
    Lund LH, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report—2013; focus theme: age[J]. J Heart Lung Transplant,2013,32(10):951-964. doi: 10.1016/j.healun.2013.08.006
    [14]
    Clarke B, Khush K. Cardiac allograft vasculopathy: an ongoing challenge in the care of heart transplant recipients[M]// Moffatt-Bruce SD. Cardiac Transplantation. Rijeka: InTech, 2012.
    [15]
    Hollis IB, Reed BN, Moranville MP. Medication management of cardiac allograft vasculopathy after heart transplantation[J]. Pharmacotherapy,2015,35(5):489-501. doi: 10.1002/phar.2015.35.issue-5
    [16]
    Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol,2014,63(25 Pt B):2960-2984. http://cn.bing.com/academic/profile?id=1967405452&encoded=0&v=paper_preview&mkt=zh-cn
    [17]
    European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)[J]. Eur Heart J,2011,32(14):1769-1818. doi: 10.1093/eurheartj/ehr158
    [18]
    Pencina MJ, D'Agostino RB Sr, Larson MG, et al. Predicting the 30-year risk of cardiovascular disease: the framingham heart study[J]. Circulation,2009,119(24):3078-3084. doi: 10.1161/CIRCULATIONAHA.108.816694
    [19]
    Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. a Meta-analysis[J]. Transplantation,2010,89(1):1-14. doi: 10.1097/TP.0b013e3181c518cc
    [20]
    Miller LW. Cardiovascular toxicities of immunosuppressive agents[J]. Am J Transplant,2002,2(9):807-818. doi: 10.1034/j.1600-6143.2002.20902.x
    [21]
    Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies)[J]. Transplantation,2011,91(9):976-983. doi: 10.1097/TP.0b013e31820c10eb
    [22]
    de Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol[J]. Mayo Clin Proc,1988,63(10):1012-1021. doi: 10.1016/S0025-6196(12)64916-7
    [23]
    Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia[J]. Am J Kidney Dis,1991,18(3):353-358. doi: 10.1016/S0272-6386(12)80095-3
    [24]
    Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients[J]. Am J Transplant,2008,8(7):1384-1392. doi: 10.1111/j.1600-6143.2008.02272.x
    [25]
    Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation[J]. Transplantation,1997,63(3):331-338. doi: 10.1097/00007890-199702150-00001
    [26]
    Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1- executive summary[J]. J Clin Lipidol,2014,8(5):473-488. doi: 10.1016/j.jacl.2014.07.007
    [27]
    Tonelli M, Wanner C, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline[J]. Ann Intern Med,2014 ,160(3):182. http://cn.bing.com/academic/profile?id=2159036586&encoded=0&v=paper_preview&mkt=zh-cn
    [28]
    中华医学会器官移植学分会. 临床诊疗指南(器官移植学分册)(2010版)[M]. 北京:人民卫生出版社, 2010.

    Branch of Organ Transplantation of Chinese Medical Association. Clinical guidelines (organ implantology volume) (2010 edition)[M]. Beijing: People's Medical Publishing House, 2010.
    [29]
    中华人民共和国卫生部疾病控制司. 中国成人超重和肥胖症预防控制指南 [M]. 北京: 人民卫生出版社, 2006.

    Disease Control in Ministry of Health of the People's Republic of China. Prevention and control guidelines on overweight and obesity in Chinese adult[M]. Beijing: People's Medical Publishing House, 2006.
    [30]
    Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2014,129(25 Suppl 2):S1-S45. doi: 10.1161/01.cir.0000437738.63853.7a
    [31]
    Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients[J]. Cochrane Database Syst Rev,2014,1:CD005019. http://cn.bing.com/academic/profile?id=1831461821&encoded=0&v=paper_preview&mkt=zh-cn
    [32]
    Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients[J]. J Heart Lung Transplant,2010,29(8):914-956. doi: 10.1016/j.healun.2010.05.034
    [33]
    Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation[J]. N Engl J Med,1995,333(10):621-627. doi: 10.1056/NEJM199509073331003
    [34]
    Wenke K, Meiser B, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial[J]. Circulation,1997,96(5):1398-1402. doi: 10.1161/01.CIR.96.5.1398
    [35]
    Kobashigawa JA, Moriguchi JD, Laks H, et al. Ten-year follow-up of a randomized trial of pravastatin in heart transplant patients[J]. J Heart Lung Transplant,2005,24(11):1736-1740. doi: 10.1016/j.healun.2005.02.009
    [36]
    Trulock EP, Christie JD, Edwards LB, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report-2007[J]. J Heart Lung Transplant,2007,26(8):782-795. doi: 10.1016/j.healun.2007.06.003
    [37]
    Johnson BA, Iacono AT, Zeevi A, et al. Statin use is associated with improved function and survival of lung allografts[J]. Am J Respir Crit Care Med,2003,167(9):1271-1278. doi: 10.1164/rccm.200205-410OC
    [38]
    Fessler MB, Young SK, Jeyaseelan S, et al. A role for hydroxy-methylglutaryl coenzyme a reductase in pulmonary inflammation and host defense[J]. Am J Respir Crit Care Med,2005,171(6):606-615. doi: 10.1164/rccm.200406-729OC
    [39]
    Morimoto K, Janssen WJ, Fessler MB, et al. Lovastatin enhances clearance of apoptotic cells (efferocytosis) with implications for chronic obstructive pulmonary disease[J]. J Immunol,2006,176(12):7657-7665. doi: 10.4049/jimmunol.176.12.7657
    [40]
    Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report[J]. JAMA,2003,289(19):2560-2572. doi: 10.1001/jama.289.19.2560
    [41]
    Watt KD, Pedersen RA, Kremers WK, et al. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study[J]. Am J Transplant,2010,10(6):1420-1427. doi: 10.1111/ajt.2010.10.issue-6
    [42]
    Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl,2013,19(1):3-26. doi: 10.1002/lt.23566
    [43]
    Orlando G, Baiocchi L, Cardillo A, et al. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension[J]. Liver Transpl,2007,13(1):46-54. doi: 10.1002/(ISSN)1527-6473
    [44]
    Sembera S, Lammert C, Talwalkar JA, et al. Frequency, clinical presentation, and outcomes of drug-induced liver injury after liver transplantation[J]. Liver Transpl,2012,18(7):803-810. doi: 10.1002/lt.v18.7
    [45]
    Perdices EV, Medina-Cáliz I, Hernando S, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry[J]. Rev Esp Enferm Dig,2014,106(4):246-254. http://cn.bing.com/academic/profile?id=2162333742&encoded=0&v=paper_preview&mkt=zh-cn
    [46]
    Calderon RM, Cubeddu LX, Goldberg RB, et al. Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma[J]. Mayo Clin Proc,2010,85(4):349-356. doi: 10.4065/mcp.2009.0365
    [47]
    Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management[J]. J Hepatol,2010,53(1):199-206. doi: 10.1016/j.jhep.2010.01.040
    [48]
    中国医师协会器官移植医师分会,中华医学会外科学分会器官移植学组,中华医学会器官移植学分会肝移植学组,等. 中国肝移植受者代谢病管理专家共识(2015版)[J].中华肝胆外科杂志,2015,21(9):577-581. http://www.cnki.com.cn/Article/CJFDTOTAL-ZYZD201503001.htm

    Branch of Organ Transplant Physician of Chinese Medical Doctor Association, Organ Transplantation Group in Branch of Surgery of Chinese Medical Association, Liver Transplantation Group in Branch of Organ Transplantation of Chinese Medical Association, et al. Expert consensus on management of metabolic diseases in Chinese liver transplant recipients (2015 edition)[J]. Chin J Hepatobiliary Surg,2015,21(9):577-581. http://www.cnki.com.cn/Article/CJFDTOTAL-ZYZD201503001.htm
    [49]
    Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients[J]. Am J Cardiol,2006,97(1):61-67. doi: 10.1016/j.amjcard.2005.07.108
    [50]
    Jose MA, Anandkumar S, Narmadha MP, et al. A comparative effect of atorvastatin with other statins in patients of hyperlipidemia[J]. Indian J Pharmacol,2012,44(2):261-263. doi: 10.4103/0253-7613.93864
    [51]
    Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med,2008,359(21):2195-2207. doi: 10.1056/NEJMoa0807646
    [52]
    Barge-Caballero G, Barge-Caballero E, Marzoa-Rivas R, et al. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results[J]. Transpl Int,2015,28(9):1034-1041. doi: 10.1111/tri.2015.28.issue-9
    [53]
    Bradford RH, Shear CL, Chremos AN, et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up[J]. Am J Cardiol,1994,74(7):667-673. doi: 10.1016/0002-9149(94)90307-7
    [54]
    Pek SL, Tavintharan S, Woon K, et al. MicroRNAs as biomarkers of hepatotoxicity in a randomized placebo-controlled study of simvastatin and ubiquinol supplementation[J]. Exp Biol Med, 2016, 241(3):317-330. doi: 10.1177/1535370215605588
    [55]
    Chen YW, Lai HW, Wang TD. Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and re-challenge[J]. Acta Neurol Taiwan,2007,16(3):163-167. http://cn.bing.com/academic/profile?id=2158452600&encoded=0&v=paper_preview&mkt=zh-cn
    [56]
    Russo MW, Hoofnagle JH, Gu J, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network[J]. Hepatology,2014,60(2):679-686. doi: 10.1002/hep.v60.2
    [57]
    Downs JR, O'Malley PG. Management of dyslipidemia for cardiovascular disease risk reduction: synopsis of the 2014 U.S. Department of Veterans Affairs and U.S. Department of Defense clinical practice guideline[J]. Ann Intern Med,2015,163(4):291-297. doi: 10.7326/M15-0840
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(12)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (67) PDF downloads(34) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return